DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 853--------------------------------------------------
       (Abst.) Tysabri improves cognitive impairment over 3 years in MS
       ...
       By: agate Date: July 7, 2015, 11:51 am
       ---------------------------------------------------------
       From PubMed, July 7, 2015:
       [quote]PLoS One. 2015 Jul 6;10(7):e0131803.
       Natalizumab Significantly Improves Cognitive Impairment over
       Three Years in MS: Pattern of Disability Progression and
       Preliminary MRI Findings
       Mattioli F1, Stampatori C1, Bellomi F1, Scarpazza C1, Capra R2.
       Author information
       1Neuropsychology Unit, Spedali Civili of Brescia, Brescia,
       Italy.
       2Multiple Sclerosis Center of the Spedali Civili of Brescia,
       Montichiari, Italy.
       Previous studies reported that multiple sclerosis (MS) patients
       treated with natalizumab for one or two years exhibit a
       significant reduction in relapse rate and in cognitive
       impairment, but the long term effects on cognitive performance
       are unknown.
       This study aimed to evaluate the effects of natalizumab on
       cognitive impairment in a cohort of 24 consecutive patients with
       relapsing remitting MS treated for 3 years.
       The neuropsychological tests, as well as relapse number and
       EDSS, were assessed at baseline and yearly for three years. The
       impact on cortical atrophy was also considered in a subgroup of
       them, and are thus to be considered as preliminary.
       Results showed a significant reduction in the number of impaired
       neuropsychological tests after three years, a significant
       decrease in annualized relapse rate at each time points compared
       to baseline and a stable EDSS.
       In the neuropsychological assessment, a significant improvement
       in memory, attention and executive function test scores was
       detected.
       Preliminary MRI data show that, while GM volume did not change
       at 3 years, a significantly greater parahippocampal and
       prefrontal gray matter density was noticed, the former
       correlating with neuropsychological improvement in a memory
       test.
       This study showed that therapy with Natalizumab is helpful in
       improving cognitive performance, and is likely to have a
       protective role on grey matter, over a three-year
       follow-up.[/quote]
       The abstract can be seen here
  HTML http://www.ncbi.nlm.nih.gov/pubmed/26148120.
       *****************************************************